March 26, 2020 / 8:45 AM / 6 days ago

BRIEF-Oncopeptides Announces 26% Overall Response Rate Of Melflufen From Pivotal Horizon Study

March 26 (Reuters) - Oncopeptides AB:

* ONCOPEPTIDES ANNOUNCES 26% OVERALL RESPONSE RATE OF MELFLUFEN IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA PATIENTS FROM THE PIVOTAL HORIZON STUDY

* RESULTS WILL FORM BASIS FOR UPCOMING NDA FOR ACCELERATED APPROVAL IN US

* HORIZON RESULTS SHOW A GOOD EFFICACY AND SAFETY PROFILE FOR MELFLUFEN IN DIFFICULT TO TREAT RRMM PATIENTS.

* DATA REINFORCE ONCOPEPTIDES’ VIEW THAT MELFLUFEN COULD PLAY AN IMPORTANT ROLE IN TREATMENT OF PATIENTS WITH RRMM Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below